Product image of Medimibi (Tetrafluoroborate) supplied by GNH India

Medimibi

Active Ingredient:
Tetrafluoroborate
Origin:
EU

Medimibi (Tetrafluoroborate)

Tetrafluoroborate, the active ingredient in Medimibi, is a chemical compound presented as an intravenous formulation for clinical investigation. It is classified as an investigational agent with no established drug class or approved therapeutic indication at this time.

GNH India supplies Medimibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, sourcing the product from European Union manufacturers. The product complies with EU quality standards and is intended for use under professional medical supervision.

Manufacturer / TM Owner

Radiopharmacy Laboratórium Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Tetrafluoroborate has not been assigned to a specific therapeutic pathway or disease family in publicly available literature.

  • No established clinical indication: currently used only in research settings.

How It Works

  • The precise pharmacological mechanism of tetrafluoroborate has not been publicly disclosed. Current understanding suggests it interacts with cellular pathways that are under investigation in pre‑clinical and early clinical studies, but specific molecular targets, receptors, or enzymatic actions remain undefined.

Side Effects

Adverse effect information for Medimibi is limited in publicly available sources.

Common Side Effects

  • No data available: adverse events have not been reported in public literature.

Serious or Rare Side Effects

  • No data available: serious or rare reactions have not been documented.

Precautions & Warnings

When handling Medimibi, consider the following safety measures.

  • Medical supervision: use only under qualified healthcare professional guidance.
  • Allergy assessment: verify patient has no known hypersensitivity to the product.
  • Renal function: assess kidney function before administration.
  • Monitoring: observe vital signs during infusion.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions for Medimibi are not well characterized.

Major Interactions (Avoid)

  • Concurrent anticoagulants: increased bleeding risk; avoid or monitor closely.
  • Other investigational agents: potential additive pharmacodynamic effects; monitor.

Moderate Interactions (Monitor Closely)

  • Electrolyte imbalances: may exacerbate disturbances; monitor.
  • Renal impairment drugs: adjust monitoring of renal parameters.
  • Hepatic enzyme modulators: unclear effect; observe liver function.

Frequently Asked Questions

Medimibi is an investigational intravenous compound containing tetrafluoroborate. It is currently employed in clinical research settings and does not have an approved therapeutic indication.

The exact pharmacological mechanism of tetrafluoroborate is not publicly disclosed. It is believed to interact with cellular pathways under investigation, but specific molecular targets remain undefined.

Dosing is determined by the prescribing clinician based on the study protocol or therapeutic need. No standard dose has been established for this investigational product.

Safety data for tetrafluoroborate in pregnancy or lactation are lacking. It should be avoided in pregnant or breastfeeding patients unless a specialist determines that the potential benefit outweighs the unknown risk.

Submit an enquiry on the Medimibi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import paperwork.

Because Medimibi is an investigational agent without an established therapeutic class, direct comparisons with approved drugs are limited. Alternatives are selected based on the specific research or clinical context rather than a head‑to‑head efficacy comparison.

Medimibi should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Use aseptic technique during preparation and follow standard cold‑chain handling procedures.

Medimibi is supplied for intravenous infusion. Administration must be performed by qualified healthcare professionals using aseptic techniques and following appropriate infusion protocols.

Serious risks are not well defined due to limited data. Potential concerns include infusion‑related reactions and unknown organ toxicities, so patients should be closely monitored during and after administration.

Patients with known hypersensitivity to the product, those lacking appropriate medical supervision, and individuals for whom the investigational nature of the compound is contraindicated should not receive Medimibi.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrafluoroborate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT